(9H-Carbazol-2-yl)boronic acid
CAS: 745783-94-2
Ref. 3D-VEB78394
| 1g | Discontinued | ||
| 5g | Discontinued | ||
| 10mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
Lomitapide is a drug for the treatment of familial chylomicronemia syndrome (FCS), which is an inherited disorder that causes very high levels of cholesterol in the blood. It is a prodrug that is converted to its active form, 9H-carbazol-2-yl)boronic acid, in the body. Lomitapide has been shown to be safe and effective in infants and children with FCS who have not responded to other treatments. The conversion of lomitapide to its active form is rapid, with peak plasma concentrations occurring within 2 hours after oral administration. Lomitapide has no known side effects or drug interactions. It does not interfere with other drugs that are being used for prevention or treatment of HIV or hepatitis B infection, cancer, or diheumatic disease. The long-term safety of lomitapide has not been established; however it appears to be well tolerated by women who are pregnant and taking
